Back to results
US 12,104,186 B2Granted
Deimmunized lysostaphin and methods of use
AssigneeInsmed Incorporated
InventorsKarl E. Griswold, Chris Bailey-Kellogg, Yoonjoo Choi, Kristina Blazanovic, Hongliang Zhao, Deeptak Verma
Life of this patent
Estimating the term…
Abstract
Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.
Claims21
A method for treating a bacterial infection that is caused by bacteria from the genus Staphylococcus having pentaglycine interpeptide cross bridges, comprising administering to a subject in need of treatment a pharmaceutical composition comprising a deimmunized lysostaphin or fragment thereof,
- wherein the deimmunized lysostaphin or fragment thereof comprises a mutation at one or more amino acid positions of Thr127, Ser126, Ser124, Ser122, Asn121, Val120, Met119, Arg118, Ile99, Lys95, Tyr93, Ser84, Leu83, Val75, Asn72, Ile70, Lys46, Ile41, Asn40, Phe38, Tyr33, Asn13, or Asn12 of SEQ ID NO:49,
- wherein the fragment comprises a catalytically active domain of a lysostaphin, and
- wherein the mutation at Ser124 is Ser124Gly,
- thereby treating the subject's bacterial infection that is caused by bacteria from the genus Staphylococcus.
1 more element
Dependencies are inferred from the claim text.